



# Application for Approval to Prescribe or Supply a Schedule 8 Medicine – Alprazolam or Flunitrazepam

as required under the Poisons and Therapeutic Goods Act 1966 (NSW)

## This form is to be used to apply for an approval to prescribe or supply a Schedule 8 benzodiazepine (alprazolam or flunitrazepam).

Practitioners can apply online through the [SafeScript NSW](#) portal. Applying via the portal allows a practitioner to receive real-time approval or a notification if an application needs to be reviewed by the NSW Ministry of Health. Practitioners can monitor the progress of their online application.

Relevant Ahpra specialists:

- **For alprazolam:** psychiatrist, medical oncologist, paediatric medical oncologist, palliative medicine physician and paediatric palliative medicine physician.
- **For flunitrazepam:** psychiatrist, medical oncologist, paediatric medical oncologist, palliative medicine physician, paediatric palliative medicine physician, respiratory and sleep medicine physician, and paediatric respiratory and sleep medicine physician.
- All medical practitioners and nurse practitioners are considered relevant practitioners when applying for 'palliative treatment'.

## Co-management arrangements and Transfer of care agreements

A **co-management arrangement** is an agreement that is established between an Ahpra registered relevant medical specialist and another prescriber. The other prescriber is usually a general practitioner, other registered medical practitioner, or nurse practitioner who agrees to partner in the care of a patient. This arrangement improves access to treatment and adds benefit to patients by combining continuity of care by their regular prescriber with specialist intervention and oversight.

Under a co-management arrangement, the relevant treating specialist is responsible for providing detailed advice and support to the other prescriber. This includes specific instruction about the treatment arrangements, pharmacotherapy treatment decisions such as medicine and dose, and ongoing review arrangements as deemed clinically appropriate. Both practitioners involved in the patient's care are responsible for ensuring that prescriptions are issued by one prescriber at any given time.

A **transfer of care agreement** involves an Ahpra registered relevant treating specialist initiating treatment and ensuring the patient is stable before directing another prescriber to continue care. Changes in medicine or increases in dose should be supported by the treating specialist.

Pharmaceutical Services recognises these arrangements when considering applications for approval from GPs, other registered medical practitioners, or nurse practitioners.



# Application for Approval to Prescribe or Supply a Schedule 8 Medicine – Alprazolam or Flunitrazepam

as required under the Poisons and Therapeutic Goods Act 1966 (NSW)

## Before starting the application:

- **If the patient is currently enrolled on the Opioid Treatment Program (OTP)**, please make sure that you have obtained written agreement from the authorised OTP prescriber for benzodiazepine treatment.
- If you are not a relevant medical specialist or in a co-management arrangement or transfer of care agreement please make sure you have sought support from a relevant medical specialist. You may be requested to provide supporting documentation. **You will be notified if additional documentation is required. Do not email or send documents unless requested.**
- **Inform the patient of the risks associated with the ongoing use of these medicines if any of the below apply:**
  - the indication for use is not listed in the approved Product Information (PI)
  - the prescribed dose exceeds that specified in the PI
  - treatment with a benzodiazepine has exceeded the duration recommended in the PI



# Application for Approval to Prescribe or Supply a Schedule 8 Medicine – Alprazolam or Flunitrazepam

as required under the Poisons and Therapeutic Goods Act 1966 (NSW)

## Clinical Advice and Support

The NSW Ministry of Health recommends the use of **SafeScript NSW** to assist practitioners to make informed clinical decisions <https://www.health.nsw.gov.au/safescript>. Consider checking **SafeScript NSW** for evidence of alerts or other issues related to the prescribing or supply of high-risk monitored medicines.

The NSW Ministry of Health recommends that all prescribing is in accordance with currently published and approved Product Information (PI), recommendations from the RANZCP, RACP and RACGP, best practice guidelines and current evidence-based medicine standards and that practitioners work within their scope of practice. Treatment should be in accordance with an amangement plan, which considers all available treatment options, including non-pharmacological strategies.

Applicants are advised to consider if the patient would benefit from a review by an **addiction medicine specialist** to manage any perceived drug dependence concerns.

Applicants can contact experienced clinical advisors and addiction medicine specialists to obtain general clinical advice and support when managing patients with drug and alcohol issues, by calling the free **Drug & Alcohol Specialist Advisory Service (DASAS)** in the Metropolitan Area: (02) 8382-1006; in Regional, Rural & Remote NSW: 1800 023 687, available 24/7.

**This advice line cannot provide support for an application for an approval.**

For more information, please visit [Pharmaceutical Services](https://www.health.nsw.gov.au/pharmaceutical-services) website

*Privacy Statement: The information set out in this form is required by the NSW Ministry of Health for the issuance of an approval to prescribe or supply a Schedule 8 medicine as required under the law. The collection, use and disclosure of the information provided will be in accordance with privacy laws. Information collected as part of the application process may be used and disclosed as part of assessing the application. Medicare numbers may be used for the purpose of patient identification. Practitioner information, and data regarding the number of patients for whom they hold approvals to prescribe or supply a Schedule 8 medicine, may also be used, and disclosed for policy and planning purposes. The information collected may be disclosed to health practitioners when necessary to facilitate coordination of treatment and patient safety or where required or authorised by law. The application may not be processed if all information and all declarations requested on the form are not completed. For further information on privacy, visit <http://www.health.nsw.gov.au/patients/privacy>*

**I confirm that I have read and understood the information contained in 'Clinical Advice and Support' and the 'Privacy Statement'**

***(This declaration is mandatory and must be completed)***

### Enquiries:

Please direct any enquiries to the Pharmaceutical Services Unit: Tel: **(02) 9424 5923** or email: [MOH-S8Auth@health.nsw.gov.au](mailto:MOH-S8Auth@health.nsw.gov.au)

### Submitting the application:

Fax completed form to the Pharmaceutical Services Unit: Fax: **(02) 9424 5889** or email: [MOH-S8Auth@health.nsw.gov.au](mailto:MOH-S8Auth@health.nsw.gov.au)

Practitioners can apply online through the [SafeScript NSW](https://www.health.nsw.gov.au/safescript) portal and in many cases receive real time approval.

### Processing Time:

Please allow up to **7 business days** for the processing of applications.



# Application for Approval to Prescribe or Supply a Schedule 8 Medicine – Alprazolam or Flunitrazepam

as required under the Poisons and Therapeutic Goods Act 1966 (NSW)

## SECTION A – PRESCRIBER DETAILS

**Prescriber Name:** (as displayed in AHPRA)

First Name(s): \_\_\_\_\_ Middle Name(s): \_\_\_\_\_

Family Name: \_\_\_\_\_

Name of Practice: \_\_\_\_\_

Address: \_\_\_\_\_ Suburb/town: \_\_\_\_\_

Postcode: \_\_\_\_\_ Telephone: \_\_\_\_\_ Fax: \_\_\_\_\_

Mobile: \_\_\_\_\_

Email: \_\_\_\_\_ (please note this email address will be used for all correspondence)

AHPRA Registration No.: \_\_\_\_\_ PBS Prescriber No.: \_\_\_\_\_

## SECTION B – PATIENT DETAILS

**Patient Name:** (as shown on Medicare card)

First Name(s): \_\_\_\_\_ Middle Name(s): \_\_\_\_\_

Family Name: \_\_\_\_\_

**Patient also known as:** (if applicable)

First Name(s): \_\_\_\_\_ Middle Name(s): \_\_\_\_\_

Family Name: \_\_\_\_\_

Address: \_\_\_\_\_ Suburb/town: \_\_\_\_\_

Postcode: \_\_\_\_\_ Medicare number: (if applicable) \_\_\_\_\_ Ref no.: \_\_\_\_\_

DVA number: (if applicable) \_\_\_\_\_

DOB: \_\_\_\_\_ (dd/mm/yyyy) Sex: Male Female Another term



# Application for Approval to Prescribe or Supply a Schedule 8 Medicine – Alprazolam or Flunitrazepam

as required under the Poisons and Therapeutic Goods Act 1966 (NSW)

## SECTION C – CO-MANAGEMENT OR TRANSFER OF CARE

I am a medical practitioner or nurse practitioner applying to prescribe or supply under a co-management arrangement or transfer of care agreement.

## SECTION D – PRE-QUESTIONS

### 1. IS THE PATIENT CURRENTLY ENROLLED ON THE OPIOID TREATMENT PROGRAM (OTP)?

**No.** Go to question 2

**Yes.** I am the authorised OTP prescriber. Go to question 2

**Yes. I am NOT the authorised OTP prescriber.** Has the patient been reviewed by the authorised OTP prescriber and written agreement to the proposed treatment obtained?

**Yes.** Go to question 2

**No.** Contact the authorised OTP prescriber and obtain written agreement before submitting this application. **This application cannot proceed** and will not be considered until written agreement is obtained.

### 2. DO YOU CONSIDER THIS PATIENT TO BE DRUG DEPENDENT?

A 'drug dependent person' means a person who has acquired, as a result of repeated administration of:

(a) a drug of addiction, or

(b) a prohibited drug within the meaning of the Drug Misuse and Trafficking Act 1985,

an overpowering desire for the continued administration of such a drug (**section 27 of the Poisons and Therapeutic Goods Act 1966**).

**Yes**

**No**

### 3. IF THE PATIENT IS NOT CONSIDERED TO BE DRUG DEPENDENT, HAVE THEY USED OR ARE THEY EXPECTED TO USE ANY OF THE DRUGS LISTED CONTINUOUSLY FOR MORE THAN TWO MONTHS?

- any Schedule 8 medicine intended for administration by injection
- any Schedule 8 medicine for inhalation, or for spray or application to mucous membranes
- buprenorphine (except transdermal preparations)
- hydromorphone
- methadone
- alprazolam
- flunitrazepam

**Yes. Approval required.** Go to Section E: Alprazolam or Section F: Flunitrazepam

**No. Approval is NOT required** for this patient at this time. Prescribing may continue without approval from NSW Ministry of Health



# Application for Approval to Prescribe or Supply a Schedule 8 Medicine – Alprazolam or Flunitrazepam

as required under the Poisons and Therapeutic Goods Act 1966 (NSW)

## SECTION E – ALPRAZOLAM

### DOSAGE

Maximum daily dose: \_\_\_\_\_ mg

Go to 'Indications' if you are prescribing for palliative treatment or are one of the following practitioners:

- psychiatrist
- palliative medicine physician or paediatric palliative medicine physician
- medical oncologist or paediatric medical oncologist
- practitioner in a co-management arrangement or transfer of care agreement

If the dose is in excess of **4mg** daily (high dose), has the patient been reviewed by a relevant medical specialist and support obtained for treatment at a high dose?

**Yes.** Go to 'Indications for Prescribing or Supply'

**No.** Go to 'Indications for Prescribing or Supply'

### INDICATIONS FOR PRESCRIBING OR SUPPLY

Generalised anxiety disorder      Panic attacks      Panic disorder

Palliative treatment

Palliative treatment means the palliative treatment of a patient who has:

- (a) an incurable, progressive, far-advanced disease or medical condition, and
- (b) a prognosis of a limited life expectancy, with death expected within the next 2 years, because of the disease or medical condition.

Other \_\_\_\_\_ (please specify).

Do you have support from a relevant medical specialist for this treatment? **Note: Relevant medical specialists do not require support.**

**Yes** or I am the relevant medical specialist. Go to **Section G: Declaration**

**No.** Refer the patient to a relevant medical specialist and obtain support. Go to **Section G: Declaration**



# Application for Approval to Prescribe or Supply a Schedule 8 Medicine – Alprazolam or Flunitrazepam

as required under the Poisons and Therapeutic Goods Act 1966 (NSW)

## SECTION F – FLUNITRAZEPAM

### DOSAGE

Maximum daily dose: \_\_\_\_\_ mg

Go to 'Indications' if you are prescribing for palliative treatment or are one of the following practitioners:

- psychiatrist
- respiratory and sleep medicine physician or a paediatric respiratory and sleep medicine physician
- palliative medicine physician or paediatric palliative medicine physician
- medical oncologist or paediatric medical oncologist
- practitioner in a co-management arrangement or transfer of care agreement

If the dose is in excess of **2mg** daily (high dose), has the patient been reviewed by a relevant medical specialist and support obtained for treatment at a high dose?

**Yes.** Go to 'Indications for Prescribing or Supply'

**No.** Go to 'Indications for Prescribing or Supply'

### INDICATIONS FOR PRESCRIBING OR SUPPLY

Severe insomnia

Palliative treatment

Palliative treatment means the palliative treatment of a patient who has:

- (a) an incurable, progressive, far-advanced disease or medical condition, and
- (b) a prognosis of a limited life expectancy, with death expected within the next 2 years, because of the disease or medical condition.

Other \_\_\_\_\_ (please specify).

Do you have support from a relevant medical specialist for this treatment? **Note: Relevant medical specialists do not require support.**

**Yes** or I am the relevant medical specialist. Go to **Section G: Declaration**

**No.** Refer the patient to a relevant medical specialist and obtain support. Go to **Section G: Declaration**



# Application for Approval to Prescribe or Supply a Schedule 8 Medicine – Alprazolam or Flunitrazepam

as required under the Poisons and Therapeutic Goods Act 1966 (NSW)

## SECTION G – DECLARATION

I confirm that the information I have provided in this application is true and complete to the best of my knowledge.

Please also tick the option which applies:

I confirm that I am the relevant treating specialist or, where required, that I have support from a relevant treating specialist for the proposed treatment.

I confirm I will seek support from a relevant treating specialist to support this application.

I confirm that I do not have support from a relevant treating specialist.

Signature: \_\_\_\_\_ **Print and Sign** \_\_\_\_\_ Date: \_\_\_\_\_ (dd/mm/yyyy)